×
About 2,919 results

ALLMedicine™ Giant Cell Tumor Center

Research & Reviews  1,415 results

Clinical outcome of a conservative approach to giant cell tumor of ankle and foot bones.
https://doi.org/10.1016/j.foot.2020.101766
Foot (Edinburgh, Scotland); Tiwari A, Verma V et. al.

May 6th, 2021 - Giant cell tumor of the bone (GCTB) affecting foot and ankle is rare, and the literature available on their clinical behavior and reconstructive options is scarce. Many authors consider these sites a special subset with high rates of local recurre...

Three-dimensional-printed porous implant combined with autograft reconstruction for gia...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082833
Journal of Orthopaedic Surgery and Research; Zhang Y, Lu M et. al.

Apr 30th, 2021 - This study is to describe the design and surgical techniques of three- dimensional-printed porous implants for proximal giant cell tumors of bone and evaluate the short-term clinical outcomes. From December 2016 to April 2020, 8 patients with gian...

The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086070
Orphanet Journal of Rare Diseases; Bernthal NM, Spierenburg G et. al.

Apr 30th, 2021 - Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm arising from the synovium of joints, bursae, and tendon sheaths affecting small and large joints. It represents a wide spectrum ranging from minimally symptomatic to massi...

The dark side of histones: genomic organization and role of oncohistones in cancer.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025322
Clinical Epigenetics; Amatori S, Tavolaro S et. al.

Apr 8th, 2021 - The oncogenic role of histone mutations is one of the most relevant discovery in cancer epigenetics. Recurrent mutations targeting histone genes have been described in pediatric brain tumors, chondroblastoma, giant cell tumor of bone and other tum...

Benign Osseous Tumors and Tumor-Like Conditions.
https://doi.org/10.1053/j.sult.2020.08.015
Seminars in Ultrasound, CT, and MR; Haygood TM, Amini B

Apr 5th, 2021 - We will provide an imaging-focused discussion of 3 benign bone tumors that do not fit in the categories of cartilaginous tumors or osteoid tumors. We have chosen giant cell tumor of bone, unicameral bone cyst, and fibrous dysplasia. All 3 of these...

see more →

Guidelines  5 results

FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor
https://dsi.com/press-releases/-/article/364091/10481984

Aug 1st, 2019 - TURALIO is the first and only approved therapy for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

NCCN Guidelines Insights: Bone Cancer, Version 2.2017
http://www.jnccn.org/content/15/2/155.full
Biermann, J.,et al

Jan 31st, 2017 - The NCCN Guidelines for Bone Cancer provide interdisciplinary recommendations for treating chordoma, chondrosarcoma, giant cell tumor of bone, Ewing sarcoma, and osteosarcoma. These NCCN Guidelines Insights summarize the NCCN Bone Cancer Panel's g.

FDA Grants Breakthrough Therapy Designation for Daiichi Sankyo and Plexxikon's Investigational CSF-1R Inhibitor Pexidartinib (PLX3397) in Tenosynovial Giant Cell Tumo
https://www.prnewswire.com/news-releases/fda-grants-breakthrough-therapy-designation-for-daiichi-sankyo-and-plexxikons-investigational-csf-1r-inhibitor-pexidartinib-plx3397-in-tenosynovial-giant-cell-tumor-300169556.html

Oct 10th, 2015 - Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational oral CSF-1R inhibitor pexidartinib ...

Bone cancer.
https://doi.org/10.6004/jnccn.2013.0088
Journal of the National Comprehensive Cancer Network : JN... Biermann JS, Adkins DR et. al.

Jun 7th, 2013 - Primary bone cancers are extremely rare neoplasms, accounting for fewer than 0.2% of all cancers. The evaluation and treatment of patients with bone cancers requires a multidisciplinary team of physicians, including musculoskeletal, medical, and r...

TURALIO™ (pexidartinib) for Healthcare Professionals
https://www.turaliohcp.com/

Discover TURALIO™ (pexidartinib), the first & only therapy indicated for tenosynovial giant cell tumor (TGCT). See full Prescribing Info & Boxed Warning.

see more →

Drugs  4 results see all →

Clinicaltrials.gov  1,457 results

Clinical outcome of a conservative approach to giant cell tumor of ankle and foot bones.
https://doi.org/10.1016/j.foot.2020.101766
Foot (Edinburgh, Scotland); Tiwari A, Verma V et. al.

May 6th, 2021 - Giant cell tumor of the bone (GCTB) affecting foot and ankle is rare, and the literature available on their clinical behavior and reconstructive options is scarce. Many authors consider these sites a special subset with high rates of local recurre...

Three-dimensional-printed porous implant combined with autograft reconstruction for gia...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082833
Journal of Orthopaedic Surgery and Research; Zhang Y, Lu M et. al.

Apr 30th, 2021 - This study is to describe the design and surgical techniques of three- dimensional-printed porous implants for proximal giant cell tumors of bone and evaluate the short-term clinical outcomes. From December 2016 to April 2020, 8 patients with gian...

The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086070
Orphanet Journal of Rare Diseases; Bernthal NM, Spierenburg G et. al.

Apr 30th, 2021 - Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm arising from the synovium of joints, bursae, and tendon sheaths affecting small and large joints. It represents a wide spectrum ranging from minimally symptomatic to massi...

Turalio - pexidartinib capsule-Daiichi Sankyo Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24c5a6f1-b640-4d14-b44b-dd293ed002b1

Apr 13th, 2021 - TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TURALIO is a kinase inhibitor i...

The dark side of histones: genomic organization and role of oncohistones in cancer.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025322
Clinical Epigenetics; Amatori S, Tavolaro S et. al.

Apr 8th, 2021 - The oncogenic role of histone mutations is one of the most relevant discovery in cancer epigenetics. Recurrent mutations targeting histone genes have been described in pediatric brain tumors, chondroblastoma, giant cell tumor of bone and other tum...

see more →

News  37 results

Pexidartinib Receives Category 1 Recommendation from NCCN
https://www.mdedge.com/sarcomajournal/article/214275/pexidartinib-receives-category-1-recommendation-nccn?channel=39313

Dec 13th, 2019 - Pexidartinib, the newly approved agent to treat patients with tenosynovial giant cell tumor (TGCT), received a category 1 recommendation from the National Comprehensive Cancer Network (NCCN) in the recent update of its Clinical Practice Guidelines.

FDA approves Turalio for symptomatic tenosynovial giant cell tumor
https://www.mdedge.com/sarcomajournal/article/205851/sarcoma-gist/fda-approves-turalio-symptomatic-tenosynovial-giant-cell?channel=27979
Mary Jo M. Dales

Aug 2nd, 2019 - Turalio (pexidartinib) capsules have been approved for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) that is associated with severe morbidity or functional limitations not responsive to improvement with surg.

U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor
https://www.reuters.com/article/us-daiichi-sankyo-fda/u-s-fda-approves-daiichi-sankyos-treatment-for-rare-joint-tumor-idUSKCN1US2C9

Aug 2nd, 2019 - (Reuters) - The U.S. Food and Drug Administration on Friday approved Daiichi Sankyo Co Ltd’s treatment for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs. The label for the treatment, Turalio, includes a boxed w...

FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor
https://dsi.com/press-releases/-/article/364091/10481984

Aug 1st, 2019 - TURALIO is the first and only approved therapy for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

FDA Approves First Drug for Tenosynovial Giant Cell Tumor
https://www.medscape.com/viewarticle/916402

Aug 1st, 2019 - The US Food and Drug Administration (FDA) today approved the novel oral therapy pexidartinib (Turalio, Daiichi Sankyo) for the treatment of tenosynovial giant cell tumor (TGCT), a rare, nonmalignant growth that can be locally aggressive and debili...

see more →

Patient Education  1 results see all →